Evolus Inc., of Newport Beach, Calif., said it closed a $100 million senior debt facility with Oxford Finance LLC to help fund the launch of Jeuveau (prabotulinumtoxinA-xvfs), approved last month by the FDA to treat severe glabellar (frown) lines in adults.